Hormones for Endo/Metabolic: 60.0% of denials overturned
In 10 California IMR decisions from 2026 to 2026, reviewers overturned 6 (60.0%). In the last five years: 60.0% of 10. 10 were medical-necessity disputes.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2026 | 10 | 60.0% |
What the findings mention
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Omnitrope. The patient has a history of growth hormone deficiency and idiopathic short stature, with persistently low growth velocity and failure to pass a growth stimulation test, confirming the diagnosis of GHD. The record shows that the patient has been receiving Omnitrope, and continued therapy is appropriate …”
“The physician reviewer found that a patient has requested authorization and coverage for Sogroya. In this case, the patient has biochemical confirmation of GHD based on a history of established pituitary dysfunction and laboratory testing results. The patient, transitioning from pediatric to adult endocrinology, requested Sogroya for the growth hormone deficiency (GHD). The provider explained that Sogroya’s once‑weekly dosing offers …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Xyosted. American Urological Association guidelines for evaluation and management of testosterone deficiency recognize testosterone enanthate, the active ingredient in Xyosted, as an accepted treatment option for hypogonadism.According to the medical records, the patient has documented low testosterone based on two testosterone measurements …”
And one the reviewer upheld
“The physician reviewer found that the patient’s parent has requested authorization and coverage for Omnitrope. The U.S. Food and Drug Administration (FDA) has approved Omnitrope (somatropin) to treat pediatric growth hormone deficiency (GHD). False‑negative results on standard provocative tests limit their utility as a sole criterion for diagnosing or excluding pediatric GHD. In this case, the patient’s clinical presentation has …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Hormones denials for Endo/Metabolic overturned?
In 10 California IMR decisions from 2026 to 2026, reviewers overturned 6 (60.0%). In the last five years: 60.0% of 10. 10 were medical-necessity disputes.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.